SABCS 2022 Meeting News Welcome Edition - 4

4
WEDNESDAY, DECEMBER 7
SCHEDULE-AT-A-GLANCE
*As of November 18, 2022 | **All times are CENTRAL Time
9:45 am - 11:00 am CT
HER2 Low: A Separate
Entity Special Session
Hall 3
Single Cell Approaches
for Translational
Research and Biomarker
Discovery
Hemisfair Ballroom 1&2
SPOTLIGHT POSTER
DISCUSSION SESSION #5:
Advances in TNBC
Biology
Stars at Night Ballroom
3&4
SPOTLIGHT POSTER
DISCUSSION SESSION #6:
Special Populations:
Male Breast Cancer/
Geriatrics
Stars at Night Ballroom
1&2
8:30 am - 9:00 am CT
William L. McGuire
Memorial Lecture:
Leveraging Preclinical
Models for Translational
Breast Cancer Research
Jeffrey Rosen, PhD
Hall 3
9:00 am - 9:45 am CT
GENERAL SESSION #2
Hall 3
10:00 am - 5:00 pm CT
EXHIBITS
Hall 2
11:00 am - 12:00 pm CT
Mini-Symposium: C.
Kent Osborne HER2
Signaling the ER Cistrome
Symposium
Hall 3
12:00 pm - 12:30 pm CT
Plenary Lecture: Lineagedefined
Metabolism of
Normal Mammary Cells
and Origins of Cancer
Metabolic Heterogeneity
Rama Khokha, PhD
Hall 3
12:30 pm - 1:00 pm CT
AACR Distinguished
Lectureship in Breast
Cancer Research
Hall 3
12:30 pm - 1:30 pm CT
Career Development Forum
Room 304
ABSTRACT PRESENTATIONS
Wednesday, December 7 | 9:00 am - 9:45 am CT | Hall 3
GENERAL SESSION #2
9:00 am - 9:15 am CT
GS2-01: Trastuzumab deruxtecan
vs physician's choice in patients
with HER2+ unresectable and/or
metastatic breast cancer previously
treated with trastuzumab emtansine:
primary results of the randomized
phase 3 study DESTINY-Breast02
9:15 am - 9:30 am CT
GS2-02: Trastuzumab deruxtecan
versus trastuzumab emtansine
in patients with HER2-positive
metastatic breast cancer: Updated
survival results of the randomized,
phase 3 study DESTINY-Breast03
HER2 LOW: A SEPARATE ENTITY SPECIAL SESSION
9:45 am - 11:00 am CT
HER2-01: Clinical and
molecular characteristics
of HER2-low/zero early
stage triple-negative breast
cancer
HER2-02: HER2-low status
is associated with worse
clinical outcomes in hormone
receptor-positive, HER2negative
advanced breast
cancer patients treated with
first-line cyclin-dependent
kinase 4/6 inhibitors plus
endocrine therapy
HER2-04: Prevalence
of HER2-low among
metastatic breast cancer
patients and their outcomes
compared to HER2 IHC 0
HER2-05: Comprehensive
genomic characterization of
HER2-low breast cancer
HER2-06: Outcome analysis
of HER2-zero or HER2-low
hormone receptor-positive
(HR+) breast cancer
patients - characterization
of the molecular phenotype
in combination with
molecular subtyping
HER2-07: Genomic
characterization of primary
and metastatic HER2-low
breast cancers
HER2-08: Molecular
characterization of HER-2
low patients identifies
basal-enriched subset with
poor clinical outcomes in
real-world data
HER2-09: Multiomics
profiling characterizes
distinct HER2-low breast
cancer subgroups in the
East Asian population
HER2-10: Dynamics of
HER2-low expression in
triple-negative breast
cancer
HER2-11: Epidemiology
and prognosis of HER2-low
breast cancer (BC) in the
National Cancer Data Base
(NCDB)
HER2-12: Genomic and
transcriptomic landscape of
HER2-low breast cancer
HER2-13: Proficiency
assessment of HER2-low
breast cancer scoring with
the Ventana PATHWAY 4B5
and Dako HercepTest HER2
9:30 am - 9:45 am CT
GS2-03: TRIO-US B-12 TALENT:
Neoadjuvant trastuzumab
deruxtecan with or without
anastrozole for HER2-low, HR+
early stage breast cancer
7:00 am - 8:15 am CT
POSTER SESSION #2
Hall 1
SPOTLIGHT POSTER
DISCUSSION SESSION #4:
1:00 pm - 2:00 pm CT
FORUM: Molecular Aspects
of DCIS Progression
Stars at Night Ballroom 3&4
Clinical Case Discussion
Session
Stars at Night Ballroom
1&2
2:00 pm - 3:00 pm CT
Clinical Controversies
Hall 3
Mini-Symposium: Late
Recurrence and Tumor
Dormancy
Stars at Night Ballroom
1&2
Forum: New Targets
and Strategies for
Immunotherapy
Stars at Night Ballroom 3&4
3:00 pm - 5:00 pm CT
EDUCATIONAL SESSION
BLOCK #2
Digital Health and
PROs in Breast Cancer
Research and Care
Hemisfair Ballroom 1&2
Antibody Drug Conjugates:
Future Directions
and Opportunities
Stars at Night Ballroom
1&2
Spatial and Single
Cell Characterization
of Breast Cancer
Progression
Stars at Night Ballroom
3&4
Breast Cancer and
Cardiovascular Toxicity:
What an Oncologist
Needs to Know
Hemisfair Ballroom 3
5:00 pm - 6:15 pm CT
POSTER SESSION #3
Hall 1
SPOTLIGHT POSTER
DISCUSSION SESSION #7:
Brain Metastasis
Stars at Night Ballroom
3&4
SPOTLIGHT POSTER
DISCUSSION SESSION #8:
Symptom Management
and Associate Toxicities
Stars at Night Ballroom
1&2
SPOTLIGHT POSTER
DISCUSSION SESSION #9:
Immune Landscape and
Microenvironments
Hemisfair Ballroom 1&2
7:00 pm - 10:00 pm CT
OPEN SATELLITE
EVENTS
Marriott Rivercenter
PRESENTER
PROFILE:
Leif W. Ellisen,
MD, PhD
Professor of Medicine,
Harvard Medical School
Program Director,
Breast Medical Oncology
MGH Cancer Center,
Boston, MA
EDUCATIONAL SESSION:
Antibody Drug Conjugates:
Future Directions and
Opportunities
Wednesday, 3:00 pm - 5:00 pm CT
Stars at Night Ballroom 1&2
PRESENTATION:
Mechanisms of resistance
Q: What is your presentation
about?
A: I will present findings from both
clinical and laboratory studies of
antibody drug conjugates (ADCs) used
in the treatment of breast and other
cancers. The presentation will follow
from the preceding presentations in this
session that focus on the design and
structure of ADCs. My talk will focus on
how the unique mechanism of action of
ADCs provides the potential for a diverse
variety of resistance mechanisms to
emerge.
Q: What makes this topic
important in 2022?
A: ADCs are proving to be paradigmchanging
drugs that have led to
improvements in overall survival for
patients with all breast cancer subtypes.
Understanding mechanisms of de
novo and acquired resistance to ADCs
will allow for more effective patient
selection, will guide the potential use
of multiple ADCs in sequence, and will
identify therapies that can be combined
with ADCs to improve responses and
outcomes.
POSTERS
assays and the impact of
pathologist training
HER2-14: HER-2 low status
in early stage invasive
lobular carcinoma of the
breast: associated factors
and outcomes in an
institutional series
HER2-15: Retrospective
Study to Estimate the
Prevalence and Describe
the Clinicopathological
Characteristics, Treatment
Patterns, and Outcomes
of HER2-Low Breast
Cancer
HER2-16: Inter-lesion
heterogeneity of HER2status
in metastatic
breast cancer: possible
implications for treatment
with anti-HER2 antibodydrug
conjugates
HER2-17: Novel quantitative
HER2 assay for determining
dynamic HER2 expression
in the HER2 IHC 0 " UltraLow "
setting: Implications
for precision therapy in
HER2- breast cancer
HER2-18: Determination
of HER2-low status in
tumors of patients with
unresectable and/or
metastatic breast cancer in
DESTINY-Breast04
HER2-19: Impact of HER2
low status on clinical
outcomes in participants
with 1-3 positive lymph
nodes, HR+/HER2- breast
cancer with recurrence score
Q: How/why did you become
involved with this area of breast
cancer research or care?
A: As the leader of a large Breast
Cancer Program at Mass General
Hospital, my team recognized
the unmet need to improve our
understanding of how to employ ADCs
most effectively for the benefit of
patients. Achieving this goal required
establishing a coordinated clinical and
translational research initiative aimed
at unraveling the complex mechanisms
of the diverse ADCs now being used in
clinical practice. 
WELCOME EDITION | SABCSMEETINGNEWS . ORG
SABCS 2022 Meeting News Welcome Edition

Table of Contents for the Digital Edition of SABCS 2022 Meeting News Welcome Edition
